- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00601224
Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia
Social Cognition and Interaction Training for Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Schizophrenia is a serious mental condition that affects approximately 1.1% of adults in the United States. People with schizophrenia experience reality perception impairments, which most commonly manifest as hallucinations, extreme paranoia, social withdrawal, and disordered thinking. Deficits in social functioning are a core feature of schizophrenia. In an effort to improve social functioning, there has been growing interest in identifying factors that underlie psychosocial impairments. One such identified factor has been neurocognition, but treatments that target solely cognitive processes do not always help overall social functioning. Social cognition and interaction training (SCIT), a group-based treatment that aims to improve both processing social information and functioning, may be an effective treatment for enhancing the social skills of people with schizophrenia. This study will compare the effectiveness of SCIT versus treatment as usual (TAU) in helping people with schizophrenia improve their social cognition and social functioning.
Participation in this single-blind study will last 11 months. All potential participants will undergo initial screening, involving the completion of a few brief tasks testing social functioning. Eligible participants will then be randomly assigned to receive SCIT plus TAU or TAU alone. Participants assigned to receive SCIT will attend twenty 1-hour weekly group sessions over 5 months. During these sessions, participants will learn ways to manage emotions, work through problems, and integrate into social situations. Participants assigned to TAU alone will meet with their case managers and healthcare provider on an as-needed basis. All participants will undergo assessments of social cognition, social functioning, and psychotic symptoms prior to treatment, immediately post-treatment, and 6 months after treatment. Each assessment will last 3 hours and will include interviews, questionnaires, and a variety of tasks testing social skills. Researchers will also contact a family member or significant other about the participant's social functioning at the same three assessment times noted above.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meets DSM-IV criteria for schizophrenia or schizoaffective disorder, based on the Structured Interview of DSM-IV patient version (SCID-P)
Exclusion Criteria:
- Meets current criteria for substance dependence, based on the SCID-P
- Meets criteria for metal retardation (e.g., has an IQ of less than 80)
- History of brain injuries
- Difficulties interacting with others, based on ratings on items from the Social Functioning Scale that tap interactional skills
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 2
Participants will receive treatment as usual
|
TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
|
|
Experimental: 1
Participants will receive social cognition and interaction training plus treatment as usual
|
SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders.
SCIT is composed of three phases: emotion training, figuring out situations, and integration.
SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Face Emotion Identification Task (FEIT)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Face Emotion Discrimination Task (FEDT)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
The Hinting Task
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
The Awareness of Social Inference Test (TASIT)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Ambiguous Intentions Hostility Questionnaire(AIHQ)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
"Beads in the Jar" Task
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Quality of Life Scale (QLS)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Positive and Negative Syndrome Scale (PANSS)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Social Skills Performance Assessment (SSPA)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Schizophrenia Cognition Rating Scale (SCoRS)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Overt Social Cognition: A Rating Scale (OSCARS)
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Lecomte Self-Esteem Scale
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
|
Number of Hospital Admissions
Time Frame: Measured at baseline, post-treatment, and 6-month follow-up
|
Measured at baseline, post-treatment, and 6-month follow-up
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David L. Penn, PhD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R34MH080010 (U.S. NIH Grant/Contract)
- DATR A2-AISZ (World Health Organization ICTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Bradley LegaRecruiting
-
Central Institute of Mental Health, MannheimRecruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
Clinical Trials on Social cognition and interaction training (SCIT)
-
National Cheng-Kung University HospitalUnknownMental Health DisorderTaiwan
-
VA Office of Research and DevelopmentRecruitingSchizophrenia | Bipolar Disorder | Depressive Disorder, Major | Stress Disorder, Post-TraumaticUnited States
-
Hôpital le VinatierCompleted
-
Bar-Ilan University, IsraelUniversity of Haifa; Israel Science FoundationCompleted
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences Institute; Carolina Institute...CompletedAutism | Social BehaviorUnited States
-
Helsinki University Central HospitalThe University of Texas Health Science Center at San Antonio; City of HelsinkiCompletedCognitive Function 1, Social | Psychotic DisorderFinland
-
VA Connecticut Healthcare SystemCompleted
-
Mental Health Services in the Capital Region, DenmarkCopenhagen Trial Unit, Center for Clinical Intervention Research; Center for...CompletedPatients at Ultra-high Risk of PsychosisDenmark
-
The University of Texas at DallasYale University; University of Texas Southwestern Medical CenterCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting